MUNICH & HAYWARD, Calif.--(EON: Enhanced Online News)--Today Definiens, the global leader in image analysis for digital pathology and diagnostics, announced the next step in its strategic roadmap for driving the clinical market for image analysis. Augmenting the earlier hiring of Ralf Huss as Chief Medical Officer, Definiens has added key business team members, Pablo Jordan and Rebecca Berghorn.
“All experts point to image analysis as one of the key drivers for adoption of digital pathology in the clinical lab. With the addition of our clinical business team leaders, we are well positioned to catalyze and shape digital pathology”
“All experts point to image analysis as one of the key drivers for adoption of digital pathology in the clinical lab. With the addition of our clinical business team leaders, we are well positioned to catalyze and shape digital pathology,” commented Definiens CEO, Thomas Heydler.
Pablo Jordan, a veteran in the pathology diagnostics industry, joins as Vice President Business Development Clinical Digital Pathology, bringing over 15 years of experience in diagnostics and personalized medicine. He was formerly Vice President Companion Diagnostics for bioMérieux, leading the company efforts to develop innovative companion diagnostics solutions. Prior to that, he held several international management roles at Roche and Ventana Medical Systems.
"I am passionate about the potential impact of Definiens' technology for tissue datafication in the discovery and development of diagnostics tests," says Jordan. "I believe we will play a major role in unlocking the tissue side of personalized medicine."
In addition, Definiens announced the appointment of Rebecca Berghorn as Director of Clinical Product Marketing. She will be responsible for leading the Product Management of Definiens' Clinical Digital Pathology business. Berghorn has an extensive track record in product management in clinical imaging applications, having worked at GE Healthcare and Philips Healthcare in key roles. Most recently she served as the Vice President for Visia Product Management at Mevis Medical Solutions.
Jordan and Berghorn will both be located in Definiens' Munich Headquarters.
Definiens is the leading provider of image analysis and data mining solutions for life science, tissue diagnostics, and clinical digital pathology. Definiens' technology provides detailed biomarker readouts from whole slide images and enables the correlation of this information with other key clinical or genomic data. Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy.
Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine, and to significantly improve the quality of patients' lives. Definiens is headquartered in Munich, Germany and has its North American headquarters in Carlsbad, CA. Further information is available at www.definiens.com.